The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 06, 2017

Filed:

Oct. 31, 2011
Applicants:

Harry E. Gruber, Rancho Santa Fe, CA (US);

Douglas J. Jolly, Encinitas, CA (US);

Derek G. Ostertag, San Diego, CA (US);

Ryan S. Burnett, San Diego, CA (US);

Amy H. Lin, San Diego, CA (US);

Tiffany Huang, San Diego, CA (US);

Joan M. Robbins, San Diego, CA (US);

Inventors:

Harry E. Gruber, Rancho Santa Fe, CA (US);

Douglas J. Jolly, Encinitas, CA (US);

Derek G. Ostertag, San Diego, CA (US);

Ryan S. Burnett, San Diego, CA (US);

Amy H. Lin, San Diego, CA (US);

Tiffany Huang, San Diego, CA (US);

Joan M. Robbins, San Diego, CA (US);

Assignee:

Tocagen Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/56 (2006.01); A61K 31/58 (2006.01); A61K 31/573 (2006.01); A61K 31/713 (2006.01); A61K 31/7088 (2006.01); A61K 39/21 (2006.01); A61K 39/395 (2006.01); C12N 15/867 (2006.01); A61K 35/768 (2015.01); A61K 9/127 (2006.01); A61N 5/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7088 (2013.01); A61K 9/127 (2013.01); A61K 31/56 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61K 31/713 (2013.01); A61K 35/768 (2013.01); A61K 39/21 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61N 5/10 (2013.01); C12N 15/867 (2013.01); C12N 2740/13032 (2013.01);
Abstract

This disclosure relates to replication competent viral vectors for treating cell proliferative disorders. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.


Find Patent Forward Citations

Loading…